Ecallantide + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blood Loss, Surgical

Conditions

Blood Loss, Surgical

Trial Timeline

May 1, 2007 → Aug 1, 2008

NCT ID

NCT00448864

About Ecallantide + Placebo

Ecallantide + Placebo is a phase 2 stage product being developed by Merck for Blood Loss, Surgical. The current trial status is terminated. This product is registered under clinical trial identifier NCT00448864. Target conditions include Blood Loss, Surgical.

What happened to similar drugs?

7 of 17 similar drugs in Blood Loss, Surgical were approved

Approved (7) Terminated (6) Active (7)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

🔄Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3

✅AliskirenNovartisApproved

✅Aliskiren and HCTZNovartisApproved

🔄Beriplex® P/N (Kcentra) + Fresh frozen plasmaCSLPhase 3

🔄Fibrinogen Concentrate (Human) (FCH) + PlaceboCSLPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00816023	Phase 2	Completed	Mar 1, 2009	Jan 1, 2010	Bloodloss
NCT00448864	Phase 2	Terminated	May 1, 2007	Aug 1, 2008	Blood Loss, Surgical

Competing Products

20 competing products in Blood Loss, Surgical

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
AZD6140 + Placebo	AstraZeneca	Phase 1	29
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
HSC835	Novartis	Phase 2	35
Aliskiren	Novartis	Approved	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Phase 1/2	32